David McNally, CEO of Titan Medical on Surgery By Robots

0

CEO, David McNally of Titan Medical, gives insight on the company’s robotic surgical system.

With multiple market research reports projecting that the robotic surgery market will exceed $20 Billion globally in the year 2021. David McNally, CEO of Titan Medical sees an opportunity to capture a significant portion of that market opportunity.

Titan Medical is the designer and developer of a versatile, advanced robotic surgical system.

“As a result improved dexterity with snake-like arms in the robot have the ability to maneuver within the body with remarkable precision yet flexibility. To access deep to reach accesses in the abdominal cavity of the body,” McNally explained.

As a result, this is one of the largest break throughs is this surgical system enters the body through one single incision in the abdomen rather than using multiple enter points.

Further, McNally is impressed by the fact there are replaceable attachments, used for cutting devices and needle drivers.

Tital Medical’ SPORT™ Surgical System is currently underdevelopment. Titan is planning to first commercialize the SPORT Surgical System in Europe followed by the United States. The world’s two largest markets for robotic surgery.

“This provides the opportunity for forward compatibility we are inspired by experienced robotic surgeons who tell us that our offering may be the next revolution and robotic surgery,” McNally said.

More About Titan Medical Inc.

A Canadian public company, headquartered in Toronto, Ontario, and listed on the Toronto Stock Exchange (TMD) and the OTCQX in the United States (TITXF).

Titan is focuses on the design, development and commercialization of new robotic surgical technologies. The Company is advancing the development of a robust product portfolio with the objective to meet current needs in surgical procedures.

For more information on Titan Medical Inc. (TMD.TO) please fill out the form below.

Request Investor Kit

Name*

Email*

*Required.